BIOMARKER:

ATM mutation

A1 | Sensitive

B | Sensitive

C1 | Sensitive

C2 | Sensitive

C3 | Sensitive

C4 | Sensitive

D | Sensitive

A1 | Resistant

B | Resistant

C1 | Resistant

C2 | Resistant

C3 | Resistant

C4 | Resistant

D | Resistant

Prostate Cancer

Solid Tumor

Chronic Lymphocytic Leukemia

Breast Cancer

Pancreatic Ductal Adenocarcinoma

Squamous Cell Carcinoma of Head and Neck

Lung Adenocarcinoma

Colorectal Cancer

Ovarian Cancer

Colon Cancer

Urothelial Cancer

Biliary Tract Cancer

HER2 Negative Breast Cancer

Non Small Cell Lung Cancer

Gastrointestinal Cancer

Small Lymphocytic Lymphoma

Pancreatic Cancer

Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma

Mantle Cell Lymphoma

Hematological Malignancies

Lung Cancer

HER2 Positive Breast Cancer

olaparib

ATM mutation|Prostate Cancer|olaparib

ATM mutation|Pancreatic Ductal Adenocarcinoma|olaparib

ATM mutation|Lung Adenocarcinoma|olaparib

ATM mutation|Ovarian Cancer|olaparib

ATM mutation|Urothelial Cancer|olaparib

ATM mutation|Biliary Tract Cancer|olaparib

ATM mutation|Pancreatic Cancer|olaparib

talazoparib

ATM mutation|Prostate Cancer|talazoparib

ATM mutation|Chronic Lymphocytic Leukemia|talazoparib

ATM mutation|Lung Adenocarcinoma|talazoparib

ATM mutation|Colon Cancer|talazoparib

rucaparib

ATM mutation|Solid Tumor|rucaparib

ATM mutation|Prostate Cancer|rucaparib

ATM mutation|Gastrointestinal Cancer|rucaparib

avelumab

ATM mutation|Solid Tumor|avelumab

ATM mutation|Prostate Cancer|avelumab

ATM mutation|Colorectal Cancer|avelumab

zanubrutinib

ATM mutation|Chronic Lymphocytic Leukemia|zanubrutinib

durvalumab + tremelimumab

ATM mutation|Squamous Cell Carcinoma of Head and Neck|durvalumab + tremelimumab

durvalumab

ATM mutation|Squamous Cell Carcinoma of Head and Neck|durvalumab

ATM mutation|HER2 Negative Breast Cancer|durvalumab

JPI-547

ATM mutation|Breast Cancer|JPI-547

APG-115

ATM mutation|Solid Tumor|APG-115

niraparib

ATM mutation|Colorectal Cancer|niraparib

BAY 1895344

ATM mutation|Solid Tumor|BAY 1895344

venetoclax + ibrutinib

ATM mutation|Mantle Cell Lymphoma|venetoclax + ibrutinib

pembrolizumab

ATM mutation|Prostate Cancer|pembrolizumab

durvalumab + gemcitabine + tremelimumab

ATM mutation|Pancreatic Ductal Adenocarcinoma|durvalumab + gemcitabine + tremelimumab

olaparib + AZD6738

ATM mutation|Ovarian Cancer|olaparib + AZD6738

irinotecan

ATM mutation|Pancreatic Ductal Adenocarcinoma|irinotecan

ABT-888 + M6620

ATM mutation|Breast Cancer|ABT-888 + M6620

abemaciclib

ATM mutation|Lung Adenocarcinoma|abemaciclib

enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan

ATM mutation|Prostate Cancer|enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan

rucaparib + PLX038

ATM mutation|Breast Cancer|rucaparib + PLX038

trastuzumab

ATM mutation|HER2 Positive Breast Cancer|trastuzumab

toripalimab-tpzi

ATM mutation|Biliary Tract Cancer|toripalimab-tpzi

LP-284

ATM mutation|Hematological Malignancies|LP-284

ribociclib

ATM mutation|Breast Cancer|ribociclib

STAR-001

ATM mutation|Lung Cancer|STAR-001

obinutuzumab

ATM mutation|Chronic Lymphocytic Leukemia|obinutuzumab

Immunotherapy

ATM mutation|Solid Tumor|Immunotherapy

ATM mutation|Colon Cancer|Immunotherapy

ATM mutation|Urothelial Cancer|Immunotherapy

ATM mutation|Non Small Cell Lung Cancer|Immunotherapy

ATM mutation|Gastroesophageal Junction Adenocarcinoma|Immunotherapy

ATM mutation|Gastric Adenocarcinoma|Immunotherapy

CDK4 inhibitor + CDK6 inhibitor

ATM mutation|Breast Cancer|CDK4 inhibitor + CDK6 inhibitor

PARP inhibitor

ATM mutation|Colorectal Cancer|PARP inhibitor

T-lymphocyte cell therapy

ATM mutation|Chronic Lymphocytic Leukemia|T-lymphocyte cell therapy

ATM mutation|Small Lymphocytic Lymphoma|T-lymphocyte cell therapy

GnRH stimulant

ATM mutation|Prostate Cancer|GnRH stimulant